Harvard Bioscience (HBIO) filed a registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to $100 million of its securities via one or more offerings.

The registration covers common stock, preferred stock, warrants, and units, according to the filing.

The company said that the terms of each offering, including prices and conditions, will be disclosed in accompanying prospectus supplements.

The net proceeds from securities sales will be used for general corporate purposes, including working capital, research, manufacturing, and potential acquisitions, Harvard Bioscience said. Funds may also be invested in short-term instruments, the company added.

Shares of the company were down 1.4% in recent Friday premarket activity.